Bristol-Myers Squibb是肿瘤学和免疫学领域的生物制药领导者，拥有强劲的分红增长记录，通过稳健的收购驱动型管线战略应对专利悬崖。
Bristol-Myers Squibb为制药行业提供有吸引力的、高于平均水平的分红收益率，得到来自已建立药物组合的强劲自由现金流和对向股东返还资本承诺的支持。
Bristol-Myers Squibb是一家顶级全球制药公司，拥有多样化的畅销药物组合，涵盖肿瘤学、心血管、免疫学和纤维化领域，年收入达到数百亿美元。
Data updated Feb 15 · Source: Twelve Data
Bristol-Myers Squibb has shown impressive recent momentum, surging nearly 35% over the past 90 days and trading near its 52-week high of $63.33. However, the 5-year return of just 1.64% highlights the longer-term challenges this large-cap pharma has faced, including patent cliffs on key drugs like Revlimid and Eliquis.
The P/E ratio of 28.65 appears elevated for a mature pharmaceutical company, though this may reflect depressed earnings from recent acquisitions and restructuring costs. BMY's dividend remains a cornerstone of the investment thesis, with a yield around 4% and a strong track record of consecutive increases befitting its Dividend Aristocrat status.
Bull case: Growing oncology and immunology pipeline (including Opdivo and recent acquisitions like Karuna Therapeutics), attractive dividend yield, and potential earnings recovery. Bear case: Significant revenue headwinds from patent expirations through 2026, heavy debt from acquisitions, and execution risk integrating new assets. BMY suits income-oriented investors willing to accept near-term uncertainty for a solid dividend and pipeline optionality.
Bristol-Myers Squibb presents a compelling value proposition within the pharmaceutical sector. Trading at a P/E ratio of roughly 11.9, the stock is priced conservatively, reflecting investor caution regarding the significant "patent cliff" facing legacy blockbusters like Revlimid and Eliquis. However, BMY is successfully executing a strategic pivot toward its new growth portfolio, including promising assets like Reblozyl and Camzyos. The stock's recent recovery from 52-week lows indicates warming market sentiment toward this turnaround story. For income-focused investors, BMY remains a standout choice due to its robust cash flow and reliable dividend history. While execution risks persist regarding pipeline delivery and debt management following recent acquisitions, the current valuation provides a reasonable margin of safety. BMY is well-suited for conservative investors seeking consistent yield and long-term capital appreciation.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
每个交易员都有一个在脑子里看起来很好的策略。回测是您发现它是否实际有效的方式。以下是如何正确测试策略、哪些指标重要，以及为什么大多数回测结果好得不真实。
Powered by Rexiew